Bibliography
- Mineralocortoid receptor antagonists for heart failure. Expert Opin Pharmacother 2011
- Gros R, Ding Q, Sklar L, GPR 30 expression is required for the mineralocortoid receptor-independent rapid vascular effects of aldosterone. Hypertension 2011;57:442-51
- Rickard AJ, Morgan J, Tesch G, Deletion of mineralocortoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009;54:537-43
- Mihailidou AS, Loan Le TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension 2009;54:1306-12
- Funder JW. Cardiac synthesis of aldosterone: going, going, gone? Endocrinology 2004;145:4793-5
- Milliez P, Girerd X, Plouin PF, Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243-8
- Levy D, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of aldosterone. J Clin Endocr Metab 2004;89:2736-40
- Epstein M, Buckalew V, Martinez FJ, Antiproteinuric effects of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002;15:24A Abstract
- Nishizuka M, Zaman M, Calhoun A. Efficiency of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16:925-30
- Funder JW, Carey RM, Fardella C, Case detection, diagnosis and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Endocrinology 2008;93:3266-81
- Sechi L, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010;23:1253-60